AMR Conference 2020

News

A new collaboration aims to the urgent fight against antimicrobial resistant bacteria. Lyon-headquartered biotech Nosopharm has teamed up with German...

FIND signs US$14.5 million grant with Unitaid to evaluate next-generation sequencing for rapid, affordable diagnosis of drug-resistant tuberculosis in...

GARDP has calls up the global community to develop five new treatments that break antimicrobial resistance (AMR) by 2025.

BioVersys has been awarded EUR 6.92 Million funding for TRIC-TB from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant...

In late April, CARB-X announced its 2019 rounds of funding to support the development of antibiotics, vaccines, biotherapeutics, diagnostics and other...

The REPAIR Impact Fund has opened its second investment proposal round to European life science companies targeting antimicrobial resistance....

BEAM Alliance has released a new position paper on PUSH Incentives called ‘Supporting financial investments on R&D to de-risk antimicrobial...

The AMR Centre has received £2.3 million to support the expansion of its pipeline of new drugs to treat drug-resistant infections.

Bacteria may travel thousands of miles through the air worldwide instead of hitching rides with people and animals, according to a new study published...

More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight...

More than 330 international experts will come together in Berlin to discuss the most pressing challenges in the fight against antimicrobial resistance...

We spoke with Kevin Outterson, Executive Director of CARB-X and speaker at AMR Conference 2019, about the recently launched expansion of the AMR...

CARB-X has expanded its reach by adding six partners from Germany, Switzerland, Denmark and India to its network.

In Mid-February, the UKRI Cross-Council AMR Initiative hosted a parliamentary panel highlighted the importance of research to tackle AMR.

German stakeholders Evotec AG and the Helmholtz Centre for Infection Research (HZI) have joined platforms in order to find novel restistance-breaking...

US researchers have shown that insect-associated microbes provide their hosts with protection against infections, suggesting that insects and their...

According to the newly published JPI AMR Research Funding Dashboard, the 22 member countries invested around 1.8bn€ in AMR research in 2017.

US stakeholders active in AMR have sent a letter to US congress representatives urging the need for pull incentives.

CARB-X funds US-company Recida Therapeutics to accelerate further development of the LpxC program to treat gram-negative superbugs.

NIAID is updating its antimicrobial resistance program and is seeking public input into strategic approaches.

CARB-X is providing funding for the further development of Polyphor’s new class of Outer Membrane Protein Targeting Antibiotics (OMPTA).

The British start-up Amprologix secured government funding to make its epidermicin NI01 antibiotic ready for the first phase of human clinical trials...

The executive board of the WHO's World Health Assembly has agreed on a draft solution on Antimicrobial Resistance. Sustainable innovation financing is...

The UN IACG has now released its draft recommendations. Until Februar 19, all stakeholders are invited to comment. A meeting in London will take place...

British researchers have discovered the antibiotic-resistant gene NDM-1 in arctic soils, far away of human presence. Only three years earlier, it was...

The World Health Organization has published a first call to establish a pre-clinical pipeline overview in the field of AMR. GARDP supports the...

In order to incentivise drug companies to re-enter development of antibiotics, the UK government announced it will establish a licence model to assure...

FDA has finalized its guidance on how to coordinate development of antimicrobials and ASTs. In February, a webinar will take place.

US agency BARDA is pushing forward its DRIVe Venture initiative. It now seeks feedback on this potential new novel public-private partnership that...

Novo Holdings has invested €18m from its €135m REPAIR Impact Fund into four companies and appointed John Rex as new chairman to the Scientific...

EMA has published a revised guideline that aims to strengthen the development of new antibacterial medicines. Over the next six month of public...

The World Health Organization has published the ten threats to global health that merit special attention from WHO and health partners in 2019. Among...

The Centers for Disease Control and Prevention (CDC) are working towards an update of their Antimicrobial Resistance Threats Report in fall 2019.

A phase 3 trial of delamanid, a newer oral drug for treating multidrug-resistant tuberculosis (MDR-TB), found no statistically significant reduction...

During the Grand Challenges meeting of Bill and Melinda Gates Foundation in October 2018, there was a panel discussion devoted to antimicrobial...

In China, two new bacteria species have been found in patients’s blood. They were found during a routine blood test, the Microbiology Society reports....

An article in Forbes explores, why more startups in animal health should develop novel antibiotics and why biotechnology innovation is needed.

Stat news reports an expert opinion according to which CDC will release an updated “Antibiotic Resistance Threats in the United States” report in the...

Researchers of Sichuan University, China, report that they have discovered two new species of resistant bacteria in the blood of patients.

Curetis’ subsidiary Ares Genetics advances AI-powered antibiotic resistance test within a new project co-funded by Vienna Business Agency.

The US Centers for Disease Control & Prevention (CDC) has awarded more than US$15m for innovative research to combat antibiotic resistance.

The French and German research ministries are launching their first joint call for projects on antimicrobial resistance.

Forge Therapeutics, Inc., a biotechnology company developing novel medicines targeting metalloenzymes, announced that it has received a second CARB-X...

Novartis is donating data from its abandoned antibiotic research programmes on Pew's open-access SPARK.

The AMR Diagnostic Challenge seeks innovative, rapid point-of-care laboratory diagnostic tests to combat the development and spread of drug resistant...

How can AMR innovation be financed? A development dialogue paper by the Dag Hammarskjöld Foundation and the ReAct Initiative attempts to answer this...

In November, the British National Institute for Health and Care Excellence (NICE) published an impact report on antimicrobial resistance. The report...

Overview about current discussion about Push and Pull incentives/ New initiative started by SMEs to propel preclinical research

Novel chemical compounds ready to be screened for antibacterial activity

Funding available for transnational research projects developing diagnostic and surveillance tools to combat AMR

Ten commandments on antimicrobial resistance

Biotech entrepreneur with TED Talk about phages and Phagomed

BaselArea.swiss successfully applied to join CARB-X Global Accelerator Network

The European Investment Bank (EIB) has lent antiinfectives company F2G Biotech Ltd €24m for antifungal research and innovation under the InnovFin...

Through its Challenge Programme, the Novo Nordisk Foundation is focusing on research on emerging infectious diseases. Applications may be submitted...

Antimicrobial resistance (AMR) has increased by 32% since 2007 in Europe, according to a brand new report.